about
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaSafety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia.Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia.Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.The genomic landscape of core-binding factor acute myeloid leukemiasMolecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemiaCombination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.A revised definition for cure of childhood acute lymphoblastic leukemia.Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaDefinition of cure in childhood acute myeloid leukemia.Skeletal manifestations of pediatric acute megakaryoblastic leukemia.Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international studyIdentification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.Spinal epidural lipomatosis in children with hematologic malignancies.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot StudyETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421.Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Effect of body mass index on the outcome of children with acute myeloid leukemia.Natural killer cell therapy in children with relapsed leukemia.Treatment outcome in older patients with childhood acute myeloid leukemiaClinical significance of in vivo cytarabine-induced gene expression signature in AML.Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
P50
Q27852520-57F82E21-5C0F-40DA-8C0F-B32861B9FA78Q28385690-9E911E9A-6045-4DDB-AC7B-B718D124813CQ33334908-2AEA2903-67A0-4144-9805-A15C04E886FDQ33598078-D97480AC-11EC-4155-9B60-EC38A8282BF6Q33645862-153A1226-ABA8-4EC6-A3ED-6FEE63D01B16Q33901968-F6351B5A-ACCB-4DDC-BF13-3CCB3A261012Q33943185-D029FA36-4EFA-4BC5-9784-C2A83319D443Q34062534-7F89D755-B70E-4AB5-99E4-3FDD908D3AA8Q34080807-E70BED58-06A6-49C3-AE2E-00163ADCF1A0Q34429332-7EA72BBF-6785-4357-A960-50E81A198C18Q34594008-D0DC1FD3-9C58-4E04-B700-D6B10ABEB628Q34598903-AE8D466C-BBD4-42C3-94CE-BE2A55687EFEQ34674124-4A21B4D3-B728-46DC-82C7-5B97E84F2D1BQ34679298-3668BE4E-D997-481B-9255-5D0AD526AD50Q34742630-524D6AB3-BE51-414B-86CC-48FA2EA20189Q34809196-29AF0631-201F-4888-BEEC-2572E4189B67Q34943824-C9E5ADBD-2083-4715-BC4D-96919054F669Q35040531-A806DA33-BA5C-4F6A-893A-7B256A5D4E31Q35048344-4FA2E38F-7850-4D4A-878B-FB550562DCE9Q35065477-4FD8966B-80AB-4F2E-9963-875948C5BB8EQ35112199-688E2C6D-789C-4C64-9324-0F0483355FB6Q35114704-05946D69-4B1E-4667-85DA-E81831B469D8Q35127974-DC9EECDE-97D0-4CBE-8E8B-ABB527C6472CQ35186322-1EBEADC1-9531-427F-A9C7-B1292EBF7244Q35202329-CDE71696-3511-4F6C-ACE1-7FC7828FB8B4Q35209900-3EDB5BDB-CAEE-4999-B4E3-D2646781EECDQ35265653-34BE6906-6B6A-4634-9FB0-1E993BA5EAE6Q35605949-274A6DFD-7340-4013-8E61-18D99B2A3A3BQ35615051-357B64D8-CE93-46E2-8C03-8703B6775D8AQ35760191-04931600-15AB-4F07-99BD-FAB81F492D34Q35936879-56D92C6E-5EA9-4328-AA23-DFDA949B9AF7Q36058482-FE9F6277-CA41-45F9-B76C-4E862B14C674Q36078671-74A4ECC2-471C-4285-8C2C-A0D7C9FA498AQ36100435-7900115A-7A9B-48C9-ABBD-C8C73D093CC6Q36182008-EC405037-2C8D-4727-8FE8-1F61F67A575AQ36210124-35A9603B-D415-42CD-B301-285333DD6A46Q36251948-93513651-676C-4736-BC00-7D6173E8D22BQ36570763-ADE97B39-5EA0-475A-AD59-90D25C852CC4Q36693136-CF6E518E-821C-4C06-993F-E94CCDB87C8BQ36873301-9F16BAB9-11C2-4F3F-BFC7-BDAEE6665419
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jeffrey Rubnitz
@ast
Jeffrey Rubnitz
@en
Jeffrey Rubnitz
@es
Jeffrey Rubnitz
@nl
type
label
Jeffrey Rubnitz
@ast
Jeffrey Rubnitz
@en
Jeffrey Rubnitz
@es
Jeffrey Rubnitz
@nl
prefLabel
Jeffrey Rubnitz
@ast
Jeffrey Rubnitz
@en
Jeffrey Rubnitz
@es
Jeffrey Rubnitz
@nl
P106
P2038
Jeffrey_Rubnitz
P31
P496
0000-0001-9885-3527